Liver and Liver-Pancreastransplantation in the Two-stage Treatment of Liver Metastasized Neuroendocrine Tumors of the Pancreas: About Three Cases Abstract #203

Introduction: Although liver transplantation is a valid option in the treatment of metastasized neuroendocrine tumors, it is not promoted because of a donor organ shortage and disappointing results in older series.
Aim(s): The key point for success in transplanting these patients lies in their selection. We will discuss the results of three patients with five-year follow up.
Materials and methods: Two patients with MEN1 syndrome and one patient with a somatostatinoma underwent pancreatectomy to treat the primary tumor site. Diffuse liver metastases, not suitable for hepatic resection, were diagnosed. In a second step, liver or liver-pancreas-transplantation was performed to treat the liver metastases. All patients were young (35, 40 and 44 years).
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr. Geert Roeyen

To read results and conclusion, please login ...

Further abstracts you may be interested in

#11 Plasma chromogranin - A response to octreotide test: Prognostic value for clinical outcome in endocrine digestive tumors
Introduction: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) expressing somatostatin receptors may be treated with somatostatin analogues (SSAs). Selection criteria are a positive Octreoscan® or a >50% hormone level decrease after octreotide s.c. injection (octreotide test) (OT). Plasma chromogranin A (CgA) is the best general GEP-NET marker, but data on CgA response to OT are scant.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: MD, PhD Sara Massironi
#530 Liver Transplantation for Metastatic Neuroendocrine Tumor: A Case Series and Proposed Selection Criteria
Introduction: Liver transplantation (LT) for neuroendocrine tumor (NET) metastases is associated with a high risk of tumor recurrence. Patient selection is the key to future success and its increased utilization.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr. Douglas Quan
Authors: Chan G, Kocha W, Reid R, Taqi A, ...
#609 Clinicopathological Analysis in 119 Cases of Rectal Neuroendocrine Tumors
Introduction: The new diagnostic criteria of the WHO 2010 Neuroendocrine Tumour Classification are not understood and applied in China.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Pathology, grading, staging
Presenting Author: Professor Po Zhao
Authors: Meng M, Zhao P, ...
#617 Incidence and Geographic Distribution of Gastroenteropancreatic (GEP) Neuroendocrine Tumors (NETs): A Systematic Review of the Literature
Introduction: Based on the literature, the world-wide incidence of neuroendocrine tumors (NETs) seems to be increasing, however, a systematic literature overview is lacking.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: MD Antongiulio Faggiano
#867 Mixed Adenoneuroendocrine Carcinoma (MANECs): A Rare and Challenging Subgroup of Neuroendocrine Neoplasia
Introduction: Mixed Adenoneuroendocrine Carcinomas (MANECs) are rare entities in which at least 30% of neoplastic cells are neuroendocrine in nature (WHO 2010 classification). They result either from two independent lesions that merge together or are unique lesions with different cell populations intermingled.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Pathology, grading, staging
Presenting Author: Dr Conor Mosli Lynch